Ciliatech Presents Groundbreaking Concept in Glaucoma Implants, First to Bypass Opening Anterior Eye Chamber

Ciliatech, an ophthalmology medtech company developing a new class of implant to treat glaucoma durably, named CID (Cilio-scleral Inter-positioning Device), today announces that the interim results of a 12-month follow-up study on its groundbreaking CID concept show strong potential to mark a new era in glaucoma surgery.

The results will be the first in-human trials to demonstrate that, in conjunction with pharmacological treatments, IOP (Intraocular pressure) can be drastically reduced without entering the eye’s anterior chamber.

Positive outcomes of Ciliatech’s 12-month follow-up study on 42 patients consolidate CID’s proof-of-concept. This consists of a simple and quick surgical technique that, unlike other intracameral implants, works successfully without generating a filtration bleb (a small blister of fluid on top of the eye’s surface or underneath the eyelid), hypotonia (intraocular pressure is too low), antimetabolites (inhibiting a particular cellular function) or risking corneal Endothelial Cell Loss (ECL)

The interim follow-up results draw upon two Ciliatech studies: SAFARI[1] 1 (12-month follow-up) and SAFARI 2 (6-month follow-up), which began in late 2020. Two cohorts of 20 and 22 patients in Yerevan, Armenia, living with open angle glaucoma, participated in the studies. They were operated on with one of the first versions of Ciliatech’s implant (SV13) in a monocentric study.